Propanc Biopharma (NASDAQ:PPCB) Shares to Reverse Split on Monday, October 26th

by · The Markets Daily

Shares of Propanc Biopharma Inc (NASDAQ:PPCB – Free Report) are set to reverse split on Monday, October 26th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Propanc Biopharma Price Performance

PPCB stock traded down $0.05 on Thursday, reaching $0.27. 206,529 shares of the company were exchanged, compared to its average volume of 1,823,659. The firm has a market capitalization of $1.71 million, a PE ratio of -0.01 and a beta of 3.53. Propanc Biopharma has a 12 month low of $0.27 and a 12 month high of $38.25. The stock’s fifty day moving average price is $0.78 and its 200 day moving average price is $1.48.

Propanc Biopharma (NASDAQ:PPCB – Get Free Report) last released its earnings results on Friday, September 25th. The company reported ($1.77) EPS for the quarter.

Propanc Biopharma announced that its Board of Directors has authorized a stock buyback program on Thursday, July 2nd that permits the company to buy back $500,000.00 in outstanding shares. This buyback authorization permits the company to repurchase up to 15.2% of its stock through open market purchases. Share buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Propanc Biopharma has a consensus rating of “Sell”.

Read Our Latest Stock Report on PPCB

About Propanc Biopharma

(Get Free Report)

Propanc Biopharma, Inc is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on proenzyme-based cancer therapies designed to target the tumor microenvironment and address cancer recurrence and metastasis.

Propanc’s lead investigational product is PRP, a formulation of two digestive proenzymes, trypsinogen and chymotrypsinogen. The company is developing PRP for potential use against advanced and recurrent cancers, including pancreatic, ovarian and colorectal cancers.

Read More